Track record · closed signal

Merck & Co., Inc. (MRK) — closed signal from September 1, 2025

Target reached Published before the outcome was known, scored automatically when the window closed on November 30, 2025 — +25.9% at the close.

Predicted vs. what happened

MRK price · publication thesis → realized outcomesplit-adjusted

$80.01 – $81.94Entry zone — fair-value band

$82.59Published — price the day we called it

$90.82Target — the price the thesis aimed for

$104.94Peak — highest point inside the window, not a realized return

$103.94Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 73 days.

At window close

+25.9%

realized, from the publication price to the last close inside the window

Peak gain

+27.1%

peak, from the publication price — not a realized return

S&P 500, same window

+6.2%

SPY over the identical days, dividend-adjusted

Window close

$103.94

last close inside the window, ended November 30, 2025

Peak price

$104.94

peak on November 25, 2025 — not a realized return

Days to target

The thesis — published September 1, 2025

Predicted growth

+12%

over the measurement window

Target price

$90.82

the price the thesis aimed for

Entry zone

$80.01 – $81.94

the fair-value band we waited for

Price at publication

$82.59

published September 1, 2025

Confidence

62%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Merck looks like a steady, larger company with solid profits and a clear path to grow. A recent report scored it 93% on a well-known value-and-growth checklist inspired by investor Peter Lynch, meaning the stock offers a good mix of fair price and growth. Buying interest is improving without getting overheated. Big drug makers can help steady a portfolio, while new medicines and execution can lift results over time.

Primary drivers

High score on a respected value-and-growth checklist, signaling balance
Reliable profits and a dividend that cushions market swings for investors
Buying interest is rising without signs of overheating in the stock price
Multiple drug prospects and solid delivery create room to grow over time

How it played out

MRK: target reached in 73 days

Lyra published MRK at 82.59 on 2025-09-01 with a short-term thesis for 12% growth toward 90.82. The thesis pointed to a 93% value-and-growth checklist score, reliable profits, a dividend, rising buying interest without overheating, and multiple drug prospects with solid delivery.

Inside the 2025-09-01 to 2025-11-30 window, MRK reached the target in 73 days. The stock peaked at 104.94 on 2025-11-25, a 27.1% gain, and ended the window at 103.94. The published thesis played out. It did more than reach the target.

What happened during the window

On 2025-10-30, Merck reported third-quarter 2025 results, and Investors.com reported sales of $17.28 billion and adjusted earnings per share of $2.58. On 2025-11-14, Investopedia reported that Merck agreed to buy Cidara Therapeutics in an all-cash deal worth $9.2 billion.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All MRK signals